Summary of results for MTX therapy in patients with LGL leukemia
| No. of patients . | Time to response, wk . | ORR, % . | CHR, % . | PR, % . | Duration of treatment, mo . | Duration of response, mo . | Comments . | Reference (year) . |
|---|---|---|---|---|---|---|---|---|
| 10 | 2-12 | 60 | 50 | 10 | NR | 12-108 | 3 MR | 68 (1994) |
| 2 | NR | 100 | NR | NR | NR | NR | NR | 59 (1994) |
| 4* | 8-12 | 100 | 67 | 33 | 16-54 | NR | 2 MR | 70 (2001) |
| 7 | 3-6 | 85 | 14 | 71 | 3-32 | NR | 2 responses after increasing doses to > 10 mg/m2 | 65 (2006) |
| 8 | NR | 38 | NR | NR | NR | NR | 1 response/3 as second-line therapy | 13 (2009) |
| 3 | NR | 66 | 33 | 33 | 12-36 | NR | NR | 69 (2010) |
| 62 | 4-12 | 55 | 21 | 34 | NR | 21 (12-60) | 12 relapses/18 under therapy | 12 (2010) |
| Total (n = 96) | 56/96 (56%) |
| No. of patients . | Time to response, wk . | ORR, % . | CHR, % . | PR, % . | Duration of treatment, mo . | Duration of response, mo . | Comments . | Reference (year) . |
|---|---|---|---|---|---|---|---|---|
| 10 | 2-12 | 60 | 50 | 10 | NR | 12-108 | 3 MR | 68 (1994) |
| 2 | NR | 100 | NR | NR | NR | NR | NR | 59 (1994) |
| 4* | 8-12 | 100 | 67 | 33 | 16-54 | NR | 2 MR | 70 (2001) |
| 7 | 3-6 | 85 | 14 | 71 | 3-32 | NR | 2 responses after increasing doses to > 10 mg/m2 | 65 (2006) |
| 8 | NR | 38 | NR | NR | NR | NR | 1 response/3 as second-line therapy | 13 (2009) |
| 3 | NR | 66 | 33 | 33 | 12-36 | NR | NR | 69 (2010) |
| 62 | 4-12 | 55 | 21 | 34 | NR | 21 (12-60) | 12 relapses/18 under therapy | 12 (2010) |
| Total (n = 96) | 56/96 (56%) |
ORR indicates overall response rate; CHR, complete hematologic response; PR, partial response; NR, not reported; and MR, molecular response.
One patient experienced MTX-related pneumonitis.